Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone908-842-0100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$35.28 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable
Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions
What is Caladrius Biosciences' stock symbol?
Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."
How were Caladrius Biosciences' earnings last quarter?
Caladrius Biosciences Inc (NASDAQ:CLBS) posted its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.04. View Caladrius Biosciences' Earnings History.
When is Caladrius Biosciences' next earnings date?
What price target have analysts set for CLBS?
4 Wall Street analysts have issued 12-month price targets for Caladrius Biosciences' shares. Their forecasts range from $6.00 to $18.50. On average, they anticipate Caladrius Biosciences' stock price to reach $10.42 in the next year. This suggests a possible upside of 273.4% from the stock's current price. View Analyst Price Targets for Caladrius Biosciences.
What is the consensus analysts' recommendation for Caladrius Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Caladrius Biosciences.
What are Wall Street analysts saying about Caladrius Biosciences stock?
Here are some recent quotes from research analysts about Caladrius Biosciences stock:
- 1. According to Zacks Investment Research, "Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. " (8/14/2019)
- 2. Chardan Capital analysts commented, "Maintaining Perform rating after better-than-expected 1Q results, but expect continued heavy investment and uncertainty around Homes. IMT EBITDA was 76%/71% above Opco/Street, significantly higher on two non-recurring accounting adjustments, and management raised the low-end of FY guidance for PA and IMT, suggesting re-acceleration. However, Offers bought 898 homes and sold 414, resulting in an increase of homes in inventory from 509 in 4Q to 993 in 1Q. This suggests some homes were older than 90 days and this was evidenced by inventory doubling over the quarter from $163M in 4Q to $325M. We remain on the sidelines on uncertainty around terminal unit economics and management pushing its five-year targets to longer" than originally assumed." (5/12/2019)
Has Caladrius Biosciences been receiving favorable news coverage?
News headlines about CLBS stock have been trending positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Caladrius Biosciences earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Caladrius Biosciences.
Are investors shorting Caladrius Biosciences?
Caladrius Biosciences saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 39,800 shares, a decline of 23.6% from the September 30th total of 52,100 shares. Based on an average daily volume of 13,300 shares, the days-to-cover ratio is presently 3.0 days. Approximately 0.4% of the shares of the company are short sold. View Caladrius Biosciences' Current Options Chain.
Who are some of Caladrius Biosciences' key competitors?
What other stocks do shareholders of Caladrius Biosciences own?
Who are Caladrius Biosciences' key executives?
Caladrius Biosciences' management team includes the folowing people:
- David J. Mazzo, President, Chief Executive Officer & Director
- Joseph Talamo, CFO, Principal Accounting Officer & Senior VP
- Douglas W. Losordo, Chief Medical Officer & Executive Vice President
- Greg Berkin, Vice President-Information Technology
- John D. Menditto, VP-Investor Relations & Corporate Communications
How do I buy shares of Caladrius Biosciences?
Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Caladrius Biosciences' stock price today?
One share of CLBS stock can currently be purchased for approximately $2.79.
How big of a company is Caladrius Biosciences?
Caladrius Biosciences has a market capitalization of $29.02 million and generates $35.28 million in revenue each year. The biotechnology company earns $-16,170,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. View Additional Information About Caladrius Biosciences.
What is Caladrius Biosciences' official website?
How can I contact Caladrius Biosciences?
Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]
MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
